I think the AffiDX SARS-Cov-2 situation will work its way out over the next couple of months.
What I found particularly encouraging* was the mention of the AffiDX BRAND, with the covid test being only the first. Not only would a £5 to £10 AffiDX test be cheaper than taking and sending a sample to a lab, it would also be immediate, thus allowing, for instance, a GP not only to identify the exact disease agent but also to prescribe the relevant antibiotic there and then rather than prescribing a general one until the sample has been tested and the result reported back. Think of all the time and human and monetary resources saved. Well worth £5 to £10. Exciting times ahead.
* As a former pharma research worker, I place no value on the therapeutics side and no way would I invest in any early stage pharma company.
@Neutronic, this wasn't called 2 weeks ago, it was announced on 25th May, some 4 weeks ago, but would have been planned some time before then. I agree though in that I think other news was expected in the meantime.
@AG1980 "Didn't he say though that this distribution deal would only be for small enterprises as Avacta were targeting the larger ones themselves to keep more margin." No he didn't say that. What he said was Avacta has set up for the larger orders because they are larger orders - large corporations, airlines, that sort of thing (as listed on the slide). You don't think Avacta want to bother processing your order for 5 LFDs do you? Margin will be smaller via distributors because the distributors will take a cut, but higher margin than satisfying those small orders directly (which could quite possibly only be done at a loss!)
Agreed Monkshood but it is dependent upon a process, which seems to involve PHE/PD, whereby the ability to detect a new variant is officially validated - and if PHE/PD aren't going to supply samples for months then...
I do. We never discovered anything (site closed now as part of global reorganistion) and even the one handed to us to develop never made it to the clinic. Moral of the story: don't expect AV6000 to sail through to the clinic without headwinds, cross winds or capsizing! (Btw, one area we worked in was targetted drug delivery)